The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of 8.6% during the forecast period of 2024-2032.
Base Year
Historical Year
Forecast Year
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes are some of the major drivers for the industry growth. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advance-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering better safety profile to the patients.
Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells. The global epidermal growth factor receptor (EGFR) inhibitors industry can be divided based on segments like indication and region.
Based on indication, the industry can be segmented into:
Looks into the regional epidermal growth factor receptor (EGFR) markets like:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global epidermal growth factor receptor inhibitors industry is being supported by the increase in the number of cancer cases such as lung cancer, colorectal cancer, breast cancer, and others. The growing incidences of cancer throughout the world also calls for more efficient therapy techniques that encourage scientists to create EGFR antibodies. Because of the busy lifestyle, excessive alcohol consumption and smoking habits, the incidence of cancer is quickly growing, particularly in regions like North America and Europe. The increasing morbidity and mortality rates among patients with cancer are leading to enhanced demand for EGFR antibodies, thus driving the market forward. Due to an enormous unmet need for new therapies to treat cancer symptoms, several pharmaceutical companies are focusing on the development of advanced EGFR inhibitors to capitalise on this enormous unmet need, which is expected to aid the industry over the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global epidermal growth factor receptor (EGFR) inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of nearly 8.6% in the forecast period of 2024-2032.
The major drivers of the industry include rising disposable incomes, increasing population, rising cases of cancer, increasing geriatric population, and the rising lifestyle changes.
The increasing cancer-related morbidity and mortality rates are expected to be the key trends guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The leading indication segments in the industry include lung, colorectal, and breast cancer, among others.
The leading players in the market are Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share